Showing results (381-390 of 395) with videos related to

Sort By:
Pageof 40
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
Nature Communications|March 31, 2019
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphomaCristina López, Kortine Kleinheinz, Sietse M Aukema, et al.
Lancet (London, England)|July 22, 2026
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trialGerald Illerhaus, Andrés J M Ferreri, Julia Wendler, et al.
Nature Medicine|January 9, 2023
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndromeErin M Parry, Ignaty Leshchiner, Romain Guièze, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical OutcomesAliki Xochelli, Panagiotis Baliakas, Ioannis Kavakiotis, et al.
Blood|March 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.
Pageof 40